Carmot Therapeutics, Inc., a biotechnology company which discovers and develops drugs for the treatment of metabolic diseases, cancer, and inflammation.
Carmot Therapeutics, Inc
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/carmot-therapeutics” connections=”true” suffix=””]
Chemotype Evolution is a proprietary technology that expands the repertoire of chemical diversity for drug discovery. enables the rapid identification of novel drugs through an evolutionary discovery paradigm. It yields lead compounds targeting incretin receptors for treatment of Type 2 diabetes, obesity, and NASH and protein-protein interactions for treatment of cancer and inflammation.
In Jan 2014, Carmot Therapeutics announced of entering into a collaboration and license agreement with Amgen, Inc. Under the terms of the agreement, Carmot will receive an upfront payment, research funding, and pre-clinical and clinical milestone payments. In addition, a royalty will be paid on commercial sales of products emerging from the collaboration. Carmot and Amgen will work together to identify and optimize drug candidates, while Amgen will be solely responsible for their clinical development.
In Jan 2018, Carmot Therapeutics, Inc. announced of a $15M financing from Horizons Ventures, existing investor The Column Group, along with private investors including Jerome Dahan. The funds will support development of the companys lead type 2 diabetes drug, a dual GLP-1R/GIPR agonist, through early clinical proof of concept.
In Aug 2017, Carmot Therapeutics, Inc. announced of financing fund worth $10.8M from an undisclosed investors.